Heffter Research Institute | Advancing Psychedelic Research
Advancing studies on psilocybin for treatment of addictions
- Website
- heffter.org · all feeds from this site
- Feed URL
https://www.heffter.org/feed/
Read it in your FeedListing reader
Or add to: Feedly Inoreader Raw feed
Latest posts
-
2023 Newletter
On September 25, 2023 we celebrated Heffter’s 30th birthday. You can see the list of the 156 research projects that have received Heffter funding since then here. As of 2020, Heffter-affiliated researchers accounted for 63% (17 of 27) of the top-cited articles on classic…
-
2022 Newsletter
Here is our annual report of our progress this past year and future plans. Heffter’s largest supported study was recently completed, “Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use…
-
With Heffter’s support the first study participant has successfully completed psilocybin-assisted therapy at Dana-Farber Cancer Institute, a principal teaching affiliate of Harvard Medical School
August 30, 2022 Dear Dr. Greer, It is my pleasure to thank you for the Heffter Research Institute’s recent gift of $138,405 to support Dr. Yvan Beaussant’s PATH study for patients receiving hospice care. Thanks to your ongoing support, the first PATH study participant has... The…
-
Johns Hopkins Medicine Receives First Federal Grant for Psychedelic Treatment Research in 50 years
Johns Hopkins Medicine was awarded a grant from the National Institutes of Health (NIH) to explore the potential impacts of psilocybin on tobacco addiction. This is the first NIH grant awarded in over a half century to directly investigate the therapeutic effects of a classic…
-
2021 NEWSLETTER
First, there have been changes at Heffter since our last newsletter. Carey Turnbull has succeeded George Greer as President. George has retired as Medical Director and is now Board Chair. Dave Nichols is Vice-President, and all three make up the Heffter Executive Committee. The…
-
Trends in The Top-Cited Articles on Classic Psychedelics
This recent publication shows that since the founding of the Heffter Research Institute in 1993, Heffter-affiliated researchers account for 63% (17 of 27) of top-cited articles on classic psychedelics. The post Trends in The Top-Cited Articles on Classic Psychedelics appeared…
-
Winter 2018/19 Newsletter
The Heffter Research Institute is celebrating 25 years of progress this year, having been incorporated in 1993! We are hearing from more and more scientists who are becoming interested in the therapeutic potential of psilocybin-assisted therapy, and 2018 has been an exciting…
-
Psilocybin-Induced Neuroplasticity in the Treatment of Major Depression
Yale University, Department of Psychiatry DOWNLOAD PDF Purpose: This study will investigate neurobiological and psychological effects of psilocybin-assisted therapy in people with major depressive disorder. The primary hypothesis is that psilocybin administered in a therapeutic…
-
Newsletter Spring 2018
2018 is bringing new opportunities for Heffter's research mission. As the FDA Phase 3 work on psilocybin-assisted therapy for depression proceeds at the Usona Institute, Heffter is moving forward with its agenda to support research to test psilocybin's healing potential for…
-
Microdosing LSD and its Research Potential
Recently there has been increased interest in microdosing LSD, that is, using doses of LSD that are not psychoactive (typically 10 micrograms). A standard recommendation is microdosing every three days. The basic idea derives from earlier studies of psychoactive doses of LSD or…